It can be inferred that inhibiting the activation of the NLRC4 inflammasome, thereby reducing the secretion of IL-1β, may represent a new therapeutic target for addressing the inflammatory response in chronic heart failure. This evidence concerns the gene IL1B and congestive heart failure.